FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

early, referring promptly to eye specialists, and weighing treatment benefits and risks on an individual basis, the health care community can integrate this new safety information into practice while preserving the substantial advantages these drugs offer.

Read more at https://www.pharmacytimes.com/view/fda-requires-class-wide-glp-1-ra-labeling-changes-for-potential-naion-risk

Customers Also Viewed

Beat the Rush, Shop Now for
the Best Selection

Recommended Just For You

Recently Viewed & Trending Items

Leave a Reply

Your email address will not be published. Required fields are marked *